AnaptysBio (NASDAQ:ANAB) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Wednesday, Zacks.com reports.

According to Zacks, “AnaptysBio, Inc. is a biotechnology company. It involved in the discovery and development of therapeutic antibodies for inflammation and immuno-oncology primarily in the Unites states. AnaptysBio, Inc. is based in San Diego, California. “

Several other brokerages have also recently commented on ANAB. HC Wainwright set a $126.00 price target on shares of AnaptysBio and gave the stock a “buy” rating in a research note on Monday, June 24th. SunTrust Banks decreased their target price on shares of AnaptysBio from $125.00 to $93.00 and set a “buy” rating on the stock in a research report on Monday, June 24th. Stifel Nicolaus set a $63.00 target price on shares of AnaptysBio and gave the company a “hold” rating in a research report on Monday. Finally, Credit Suisse Group decreased their target price on shares of AnaptysBio from $79.00 to $75.00 and set a “neutral” rating on the stock in a research report on Friday, August 9th. Four investment analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $111.50.

ANAB stock traded up $2.47 during mid-day trading on Wednesday, hitting $51.46. The company had a trading volume of 28,117 shares, compared to its average volume of 268,413. The company has a market capitalization of $1.32 billion, a P/E ratio of -20.51 and a beta of 1.37. AnaptysBio has a 12-month low of $46.55 and a 12-month high of $110.00. The firm’s 50-day moving average price is $53.91.

AnaptysBio (NASDAQ:ANAB) last announced its quarterly earnings results on Thursday, August 8th. The biotechnology company reported ($0.89) EPS for the quarter, topping the consensus estimate of ($0.97) by $0.08. The company had revenue of $5.00 million during the quarter. The firm’s quarterly revenue was up 4900.0% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.57) EPS. Sell-side analysts anticipate that AnaptysBio will post -3.76 earnings per share for the current year.

In related news, CEO Hamza Suria sold 22,428 shares of the stock in a transaction dated Monday, June 10th. The shares were sold at an average price of $73.76, for a total value of $1,654,289.28. Following the sale, the chief executive officer now directly owns 31,524 shares of the company’s stock, valued at approximately $2,325,210.24. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Marco Londei sold 10,060 shares of the stock in a transaction dated Tuesday, June 4th. The stock was sold at an average price of $73.06, for a total transaction of $734,983.60. Following the completion of the sale, the insider now directly owns 32,437 shares in the company, valued at $2,369,847.22. The disclosure for this sale can be found here. 14.00% of the stock is currently owned by corporate insiders.

Institutional investors have recently bought and sold shares of the stock. Aperio Group LLC purchased a new stake in AnaptysBio in the 2nd quarter worth about $45,000. Zurcher Kantonalbank Zurich Cantonalbank raised its position in AnaptysBio by 30.8% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,298 shares of the biotechnology company’s stock worth $73,000 after purchasing an additional 306 shares during the period. Amundi Pioneer Asset Management Inc. purchased a new stake in AnaptysBio in the 1st quarter worth about $110,000. Bank of Montreal Can bought a new position in AnaptysBio in the 2nd quarter worth about $115,000. Finally, Whittier Trust Co. bought a new position in AnaptysBio in the 2nd quarter worth about $213,000.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical stage biotechnology company, engages in developing antibody product candidates focused on unmet medical needs in inflammation. The company's products include Etokimab, an anti-interleukin (IL)-33 program for the treatment of atopic dermatitis, eosinophilic asthma, and chronic rhinosinusitis with nasal polyps; ANB019, an anti-IL-36 receptor program for generalized pustular psoriasis and palmo-plantar pustular psoriasis; and anti-inflammatory checkpoint modulators for inflammatory diseases.

See Also: Short Selling – Explanation For Shorting Stocks

Get a free copy of the Zacks research report on AnaptysBio (ANAB)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for AnaptysBio (NASDAQ:ANAB)

Receive News & Ratings for AnaptysBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio and related companies with MarketBeat.com's FREE daily email newsletter.